|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The central hypothesis motivating this study is that remote patient monitoring (RPM) of infectious disease patients can efficiently facilitate self-isolation. Additionally, RPM can assist in more rapid identification of patients at risk, facilitate detection of patient deterioration, and enable early interventions, all of which play a vital role in resource utilization and outcomes.
Description: compare the number of in-patient admissions between the monitored and non-monitored patientsMeasure: Monitored versus Non-Monitored in-patient admission Time: 14 days
Description: compare the number of Emergency Department visitsMeasure: Emergency Department Visits Time: 14 days
Description: Length of stay of subject if hospitalizedMeasure: Length of stay Time: 14 days
Description: Survey given to patient to ask about satisfactionMeasure: patient satisfaction Time: 14 days
Description: How often does a subject end up getting mechanical ventilation or ECMOMeasure: the incidence of mechanical ventilation and ECMO Time: 14 days
Description: events requiring extended hospital stayMeasure: serious adverse events Time: 14 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports